Cargando…

Effect of COVID-19 Pandemic on Patients Who Have Undergone Liver Transplantation Because of Hepatocellular Carcinoma

BACKGROUND AND AIM: Many clinical studies have shown that the COVID-19 case fatality rate is higher in older patients, those with comorbidities, those with immunosuppressive conditions, and those who stay in the intensive care unit. This study aims to evaluate the clinical outcomes of 66 liver trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbulut, Sami, Bagci, Nazlican, Akyuz, Musap, Garzali, Ibrahim Umar, Saritas, Hasan, Tamer, Murat, Ince, Volkan, Unsal, Selver, Aloun, Ali, Yilmaz, Sezai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028347/
https://www.ncbi.nlm.nih.gov/pubmed/37137762
http://dx.doi.org/10.1016/j.transproceed.2023.01.038
_version_ 1784909931126718464
author Akbulut, Sami
Bagci, Nazlican
Akyuz, Musap
Garzali, Ibrahim Umar
Saritas, Hasan
Tamer, Murat
Ince, Volkan
Unsal, Selver
Aloun, Ali
Yilmaz, Sezai
author_facet Akbulut, Sami
Bagci, Nazlican
Akyuz, Musap
Garzali, Ibrahim Umar
Saritas, Hasan
Tamer, Murat
Ince, Volkan
Unsal, Selver
Aloun, Ali
Yilmaz, Sezai
author_sort Akbulut, Sami
collection PubMed
description BACKGROUND AND AIM: Many clinical studies have shown that the COVID-19 case fatality rate is higher in older patients, those with comorbidities, those with immunosuppressive conditions, and those who stay in the intensive care unit. This study aims to evaluate the clinical outcomes of 66 liver transplant (LT) patients with primary liver cancer who were exposed to COVID-19 infection. METHODS: Demographic and clinical data of 66 patients with primary liver cancer (hepatocellular carcinoma = 64, hepatoblastoma = 1, cholangiocarcinoma = 1) who underwent LT in our institute and were exposed to COVID-19 infection between March 2020 and November 2021 were analyzed in this cross-sectional study. The following data of the patients were recorded: age, sex, body mass index (kg/m(2)), blood group, underlying primary liver disease, smoking, tumor characteristics, post-transplant immunosuppressive agents, COVID-19 symptoms, hospitalization, intensive care unit stay, intubation, and other clinical features. RESULTS: There were 55 (83.3%) male and 11 (16.7%) female patients, with a median age of 58 years. Sixty-four patients were exposed to COVID-19 only once, whereas the remaining 2 patients were exposed 2 and 4 times, respectively. After exposure to COVID-19, it was determined that 37 patients used antiviral drugs, 25 were hospitalized, 9 were followed in the intensive care unit, and 3 were intubated. One intubated patient was under hospital follow-up because of biliary complications before exposure to COVID-19, and this patient died from sepsis. CONCLUSION: The low mortality rate of LT patients with primary liver cancer exposed to COVID-19 infection can be attributed to background immunosuppression that prevents cytokine storm. However, it is appropriate to support this study with multicenter studies to make strong comments on this issue.
format Online
Article
Text
id pubmed-10028347
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-100283472023-03-21 Effect of COVID-19 Pandemic on Patients Who Have Undergone Liver Transplantation Because of Hepatocellular Carcinoma Akbulut, Sami Bagci, Nazlican Akyuz, Musap Garzali, Ibrahim Umar Saritas, Hasan Tamer, Murat Ince, Volkan Unsal, Selver Aloun, Ali Yilmaz, Sezai Transplant Proc Article BACKGROUND AND AIM: Many clinical studies have shown that the COVID-19 case fatality rate is higher in older patients, those with comorbidities, those with immunosuppressive conditions, and those who stay in the intensive care unit. This study aims to evaluate the clinical outcomes of 66 liver transplant (LT) patients with primary liver cancer who were exposed to COVID-19 infection. METHODS: Demographic and clinical data of 66 patients with primary liver cancer (hepatocellular carcinoma = 64, hepatoblastoma = 1, cholangiocarcinoma = 1) who underwent LT in our institute and were exposed to COVID-19 infection between March 2020 and November 2021 were analyzed in this cross-sectional study. The following data of the patients were recorded: age, sex, body mass index (kg/m(2)), blood group, underlying primary liver disease, smoking, tumor characteristics, post-transplant immunosuppressive agents, COVID-19 symptoms, hospitalization, intensive care unit stay, intubation, and other clinical features. RESULTS: There were 55 (83.3%) male and 11 (16.7%) female patients, with a median age of 58 years. Sixty-four patients were exposed to COVID-19 only once, whereas the remaining 2 patients were exposed 2 and 4 times, respectively. After exposure to COVID-19, it was determined that 37 patients used antiviral drugs, 25 were hospitalized, 9 were followed in the intensive care unit, and 3 were intubated. One intubated patient was under hospital follow-up because of biliary complications before exposure to COVID-19, and this patient died from sepsis. CONCLUSION: The low mortality rate of LT patients with primary liver cancer exposed to COVID-19 infection can be attributed to background immunosuppression that prevents cytokine storm. However, it is appropriate to support this study with multicenter studies to make strong comments on this issue. Elsevier Inc. 2023-06 2023-03-21 /pmc/articles/PMC10028347/ /pubmed/37137762 http://dx.doi.org/10.1016/j.transproceed.2023.01.038 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Akbulut, Sami
Bagci, Nazlican
Akyuz, Musap
Garzali, Ibrahim Umar
Saritas, Hasan
Tamer, Murat
Ince, Volkan
Unsal, Selver
Aloun, Ali
Yilmaz, Sezai
Effect of COVID-19 Pandemic on Patients Who Have Undergone Liver Transplantation Because of Hepatocellular Carcinoma
title Effect of COVID-19 Pandemic on Patients Who Have Undergone Liver Transplantation Because of Hepatocellular Carcinoma
title_full Effect of COVID-19 Pandemic on Patients Who Have Undergone Liver Transplantation Because of Hepatocellular Carcinoma
title_fullStr Effect of COVID-19 Pandemic on Patients Who Have Undergone Liver Transplantation Because of Hepatocellular Carcinoma
title_full_unstemmed Effect of COVID-19 Pandemic on Patients Who Have Undergone Liver Transplantation Because of Hepatocellular Carcinoma
title_short Effect of COVID-19 Pandemic on Patients Who Have Undergone Liver Transplantation Because of Hepatocellular Carcinoma
title_sort effect of covid-19 pandemic on patients who have undergone liver transplantation because of hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028347/
https://www.ncbi.nlm.nih.gov/pubmed/37137762
http://dx.doi.org/10.1016/j.transproceed.2023.01.038
work_keys_str_mv AT akbulutsami effectofcovid19pandemiconpatientswhohaveundergonelivertransplantationbecauseofhepatocellularcarcinoma
AT bagcinazlican effectofcovid19pandemiconpatientswhohaveundergonelivertransplantationbecauseofhepatocellularcarcinoma
AT akyuzmusap effectofcovid19pandemiconpatientswhohaveundergonelivertransplantationbecauseofhepatocellularcarcinoma
AT garzaliibrahimumar effectofcovid19pandemiconpatientswhohaveundergonelivertransplantationbecauseofhepatocellularcarcinoma
AT saritashasan effectofcovid19pandemiconpatientswhohaveundergonelivertransplantationbecauseofhepatocellularcarcinoma
AT tamermurat effectofcovid19pandemiconpatientswhohaveundergonelivertransplantationbecauseofhepatocellularcarcinoma
AT incevolkan effectofcovid19pandemiconpatientswhohaveundergonelivertransplantationbecauseofhepatocellularcarcinoma
AT unsalselver effectofcovid19pandemiconpatientswhohaveundergonelivertransplantationbecauseofhepatocellularcarcinoma
AT alounali effectofcovid19pandemiconpatientswhohaveundergonelivertransplantationbecauseofhepatocellularcarcinoma
AT yilmazsezai effectofcovid19pandemiconpatientswhohaveundergonelivertransplantationbecauseofhepatocellularcarcinoma